| Name | Plerixafor octahydrochloride |
| Description | Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. |
| Cell Research | Plerixafor is dissolved in DMSO and then diluted with appropriate medium[2]. U87 mg cells are seeded in 96-well plates at the density of 6×103 cells in 200 μL/well and treated with CXCL12, Plerixafor or with peptide R, as described in the previous "Treatments" section. MTT (5 μg/mL) is added at each time point (24, 48, 72 h) during the final 2 h of treatment. After removing cell medium, 100 μL DMSO are added and optical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicates from three independent experiments[2]. |
| In vitro | AMD 3100 can inhibit the replication of low-passage clinical HIV-1 isolates (K31, D370, K6/-2, HEM, and JRCSF) in primary T4 lymphocytes (EC50s: 0.16-1.5 ng/ml; EC90s: 0.36-4.7 ng/ml). In primary monocytes, AMD 3100 was active against HIV-1 (K31 and SF-162) at EC50s of 0.28-7.2 ng/mL and EC90s of 0.68-12 ng/mL. |
| In vivo | Serum drug levels in rabbits given AMD 3100 (10 mg/kg) by the subcutaneous route were determined by a bioassay based on the EC50 of the compound required to inhibit HIV-1 cytopathicity in MT-4 cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : Insoluble
H2O : 119.17 mg/mL (150 mM), Sonication is recommended.
|
| Keywords | Plerixafor octahydrochloride | AMD 3100 | Virus Protease | SID 791 | SID-791 | JM-3100 Octahydrochloride | AMD-3100 Octahydrochloride | SID-791 Octahydrochloride | JM3100 Octahydrochloride | AMD-3100 | Plerixafor Octahydrochloride | AMD3100 8HCl | AMD3100 | SID791 | HIV | CXC chemokine receptors | SID 791 Octahydrochloride | AMD3100 Octahydrochloride | AMD3100 octahydrochloride | CXCR | Human immunodeficiency virus | inhibit | JM 3100 | Inhibitor | JM-3100 | AMD 3100 Octahydrochloride | JM 3100 Octahydrochloride | Plerixafor | SID791 Octahydrochloride | JM3100 |
| Inhibitors Related | Stavudine | Emtricitabine | Lamivudine |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | GPCR Compound Library |
United States
